Laurus Labs' stock has seen significant growth in 2025, rising 82% year-to-date and reaching a new high of 1,095. This performance is driven by a 33% year-on-year revenue increase to 3,223 crore in the first half of FY26, attributed to strong growth in its CDMO and Generics divisions. The company's EBITDA margins also improved significantly due to product mix and operational leverage, contributing to a net profit of 358 crore.